Background: CVD is the leading cause of mortality worldwide and c

Background: CVD is the leading cause of mortality worldwide and cardiac troponins have been the cornerstone in the risk stratification of individuals with and without CVD. In a community-based population study, hsTropI may identify high-risk Erlotinib ic50 individuals several years prior to CVD-related mortality but this association using this newly established troponin assay has not been

validated in other population cohorts and it remains unclear whether this association is modified by baseline kidney function. Methods: This was a prospective observational study of 1,235 women over the age of 70 from the Calcium Intake Fracture Outcome Study. Baseline hsTropI was measured by immunoassay with level of detection of 4 ng/L. Association between hsTropI and 10-year risk of CVD hospitalisation/mortality was examined using Cox regression analysis. Results: Mean ± SD of CKD-EPI estimated glomerular filtration rate (eGFR) and hsTropI were 66.6.3 ± 13.3 mL/min/1.73 m2

and 6.8 ± 11.5 ng/L respectively. Less than 2% of participants had prevalent selleck products kidney disease. Above-median hsTropI was associated with a greater risk of CVD hospitalisation/mortality in the model adjusted for age, baseline eGFR, prevalent vascular and renal disease, diabetes and hypertension

(hazard ratio [HR] 1.56, 95%CI 1.17–2.09, P = 0.003). Baseline eGFR was an effect modifier between hsTropI and CVD hospitalisation/mortality (p-value for interaction 0.03). When stratified by eGFR < or ≥60 mL/min/1.73 m2, the association between above-median hsTropI and CVD hospitalisation/mortality was present only for participants with eGFR ≥60 mL/min/1.73 m2 (HR 1.73, 95%CI 1.16, 2.59, P = 0.007). Conclusions: The association between the newly established hsTropI and CVD hospitalisation/mortality may not be as robust in of elderly women with reduced kidney function but this finding requires confirmation in larger studies. 182 THE IMPACT OF ADVANCE CARE PLANNING FOR RENAL PATIENTS D MAWREN1, K DETERING1, D CHAFFERS1, S FRASER1, D POWER2, W SILVESTER1 1Respecting Patient Choices, Austin Health, Melbourne; 2Department of Nephrology, Austin Health, Melbourne, Australia Aim: To evaluate the impact of the introduction of ACP to the Austin Hospital renal unit. Background: Research indicates that renal patients are uninformed about care options and have limited knowledge about illness prognosis and trajectories.

Comments are closed.